Trial Profile
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ADVANCE
- Sponsors Biogen
- 28 Oct 2022 Results (of studies ADVANCE, ASCEND, DECIDE and EXTEND) assessing Machine learning parcellation of multiple sclerosis lesions into texturally consistent super-voxels for lesion classification presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 22 Apr 2021 Results of data from ADVANCE (n=1512) used for training/validation and ASCEND (n=886) for testing presented at the 73rd Annual Meeting of the American Academy of Neurology
- 12 Oct 2018 Results of a post-hoc analysis assessing the reduction of black holes evolved from acute MRI lesions in multiple sclerosis patients, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.